頁籤選單縮合
題 名 | 免疫檢查點抑制劑之相關不良反應處置及臨床考量=Management of Immune Checkpoint Inhibitors-associated Adverse Effect and Clinical Considerations |
---|---|
作 者 | 王君如; 許芳瑞; 高啟蘭; 黃婉翠; | 書刊名 | 藥學雜誌 |
卷 期 | 35:4=141 2019.12[民108.12] |
頁 次 | 頁14-19 |
分類號 | 418.29 |
關鍵詞 | 免疫檢查點抑制劑; 免疫相關的副作用; Immune checkpoint inhibitors; Immune-related adverse events; |
語 文 | 中文(Chinese) |
中文摘要 | 癌症免疫治療中目前最熱門的為免疫檢查點抑制劑 ( immune che ckpoint inhibitors),它主要包含了三大類的藥品:anti-cytotoxic T-lymphocyte antigen 4(anti- CTLA-4),anti-programmed cell death 1(anti-PD-1) 及 anti-programmed cell death ligand 1(anti-PD-L1),臨床試驗皆證實比傳統治療上有較好的治療效果,可以延長病人的壽 命,但是伴隨著使用此類藥品的病人數增加,越來越多的毒性被報導出來,尤其是因 為此類藥品刺激自體免疫來對抗癌細胞,而自體免疫的活性過高,反而會影響到全身 的器官造成發炎,目前比較常見的免疫相關副作用有皮膚、內分泌、肝臟、腸胃道及 肺臟方面,針對這些不良反應我們綜整出目前的處置方式及考量點,供臨床上使用及 注意。期望免疫檢查點抑制劑能更有效及安全的用於癌症病人。 |
英文摘要 | Immune checkpoint inhibitors (ICIs) are novel treatment options for cancer patients. ICIs include cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed cell death 1 (PD- 1) and programmed cell death ligand 1 (PD-L1). Several clinical trials indicated that ICIs achieved better treatment outcomes than conventional chemotherapy and extended lifespan of the patients. However, notable drug-associated adverse events of collateral damage to major organs due to enhanced immune response, or immune-related adverse events (irAEs), were frequently reported. The commonly seen irAEs affected skin, endocrine, liver, gastrointestinal tract and lungs. In this article, we summarize ICIs-related irAEs, clinical issues and current approach for the management of ICIs-related irAEs. |
本系統中英文摘要資訊取自各篇刊載內容。